Search
Unicycive Therapeutics Inc
UNCYAdd to Watchlist
5.730USD
+0.450+8.52%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
152.99MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+8.52%
5 Days
-30.21%
1 Month
-20.75%
6 Months
-1.21%
Year to Date
-0.69%
1 Year
+23.49%
Key Figures
5.300Open
5.790High
2.99MVolume
LossP/E TTM
0.44P/E Dynamic
--Dividend TTM
13.53%Turnover Ratio
5.280Prev. Close
5.100Low
11.77MTurnover
LossP/E Static
4.20P/B
0.00%Div Yield TTM
-86.51%ROA
11.00052wk High
0.74Volume Ratio
-37.82MNet Profit
22.11MShares
-2.2515EPS TTM
1.73Beta
-162.89%ROE
3.71052wk Low
13.07%Amplitude
100.00%Gross Margin
152.99MMarket Cap
-5.94Reward/Risk
4.49%Risk Rate
TradingKey Stock Score of Unicycive Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Unicycive Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 187 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.14.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Unicycive Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Unicycive Therapeutics Inc Highlights
StrengthsRisks
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Undervalued
The company’s latest PE is -2.54, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.56M shares, increasing 4.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.83.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
35.143
Target Price
+356.40%
Upside Space
Unicycive Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Unicycive Therapeutics Inc Info
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Ticker SymbolUNCY
CompanyUnicycive Therapeutics Inc
CEOGupta (Shalabh)
Websitehttps://unicycive.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52974.700
+132.200 (+0.25%)
29586.700
+275.300 (+0.94%)
7504.100
+32.600 (+0.44%)
15021.000
+218.000 (+1.47%)
69546.000
+1398.000 (+2.05%)
6379.000
+26.200 (+0.41%)
68.913
+0.569 (+0.83%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4179.700
+57.790 (+1.40%)
FAQs
What is the current price of Unicycive Therapeutics Inc (UNCY)?
The current price of Unicycive Therapeutics Inc (UNCY) is 5.73.
What is the symbol of Unicycive Therapeutics Inc?
The ticker symbol of Unicycive Therapeutics Inc is UNCY.
What is the 52-week high of Unicycive Therapeutics Inc?
The 52-week high of Unicycive Therapeutics Inc is 11.00.
What is the 52-week low of Unicycive Therapeutics Inc?
The 52-week low of Unicycive Therapeutics Inc is 3.71.
What is the market capitalization of Unicycive Therapeutics Inc?
The market capitalization of Unicycive Therapeutics Inc is 126.71M.
Is Unicycive Therapeutics Inc (UNCY) currently rated as Buy, Hold, or Sell?
According to analysts, Unicycive Therapeutics Inc (UNCY) has an overall rating of Buy, with a price target of 35.14.
What is the Earnings Per Share (EPS TTM) of Unicycive Therapeutics Inc (UNCY)?
The Earnings Per Share (EPS TTM) of Unicycive Therapeutics Inc (UNCY) is -1.67.